Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02472548
Other study ID # CI1204
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 2015
Est. completion date March 14, 2017

Study information

Verified date January 2020
Source Dalhousie University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Administration of DPX-RSV(A), a Respiratory Syncytial Virus vaccine containing Respiratory Syncytial Virus (RSV) SHe antigen and DepoVaxTM adjuvant to healthy adults ≥50-64 years of age.


Description:

This is a phase 1, First in Humans, randomized (2:2:1) observer blind, controlled, dose ranging, multi-arm parallel-group clinical trial in healthy persons 50 to 64 years of age to assess the safety and immunogenicity of two dose levels of a novel vaccine formulation DPX-RSV(A) consisting of a synthetic Respiratory Syncytial Virus SHe antigen combined with a novel adjuvant DepoVaxTM, compared to the antigen combined with the commonly used adjuvant Aluminum hydroxide, and to a saline placebo control.

The study will evaluate two different doses of DPX-RSV(A) and two doses of the RSV SHe antigen with aluminum hydroxide (RSV(A)-Alum), and a placebo control. The study is randomized, controlled, and observer-blinded in order that allocation to treatment is concealed from the investigative team and the participant. The inclusion of comparator groups (a placebo control group and the RSV(A)-Alum) allows for estimation of the attributable risk of adverse events. Since the study vaccines are not identical in appearance, an unblinded study nurse who has no other role in the study will administer the study vaccines.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date March 14, 2017
Est. primary completion date March 14, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 64 Years
Eligibility Inclusion Criteria:

- Age 50-64 years, inclusive.

- Good general health status, as determined by history and physical examination no greater than 30 days prior to administration of the test article.

- Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of Diary Cards, return for follow-up visits).

- Written informed consent obtained from the participant.

- If female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 180 days after injection. (Please refer to the glossary for the definition of child-bearing potential and adequate contraception).

Exclusion Criteria:

- Use of any investigational or non-registered product (drug or vaccine) other than the study product within 28 days preceding the dose of study product, or planned use during the study period.

- Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).

- Planned administration/ administration of a vaccine/product not foreseen by the study protocol within the period starting 28 days before injection of a study vaccine and ending 84 days after.

- Administration of immunoglobulins and/or any blood products within the 3 months preceding the dose of study product or planned administration during the study period.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. (Laboratory testing for HIV, Hepatitis C and Hepatitis B will be performed during the screening visit).

- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drug within 6 months prior to the product dose (for corticosteroids, this will mean prednisone = 20 mg/day, or equivalent). Inhaled and topical steroids are allowed.

- Family history of congenital or hereditary immunodeficiency.

- History of or current autoimmune disease.

- History of hypersensitivity to any test article constituent or products used during the course of study procedures.

- Known or suspected hypersensitivity to any ingredient in the formulation or component of the container.

- Pregnant or lactating female.

- Female planning to become pregnant or planning to discontinue contraceptive precautions within 180 days of study vaccine receipt.

- Any hematological (hemoglobin level, white blood cell [WBC], and platelet count) and biochemical (alanine aminotransferase [ALT], aspartate aminotransferase [AST], blood urea nitrogen [BUN] and creatinine) abnormality as per local laboratory normal values considered clinically significant by the investigator.

- Transient mild laboratory abnormalities may be rescreened and the participant will be deemed eligible if the laboratory repeat test is normal as per local laboratory normal values and investigator assessment.

- Any acute or chronic, clinically significant disease, as determined by physical examination or laboratory screening tests.

- Malignancies within previous 5 years (excluding non-melanic skin cancer) and lymphoproliferative disorders.

- Current alcoholism and/or drug abuse.

- Acute disease and/or fever at the time of Screening = 38°C

1. Fever is defined as temperature = 38° /100.4°F by any route; the preferred route for recording temperature in this study will be oral.

2. Participants with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.

3. Participants with acute disease and/ or fever at the time of Screening may be re-screened at a later date.

- Planned move to a location that will prohibit participating in the trial until study end.

- Any other condition that the investigator judges may interfere with study procedures (e.g. drawing blood) or findings (e.g. immune response).

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
DPX-RSV(A)
Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
RSV(A)-Alum
Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
Other:
Placebo
Normal saline (0.9 % sodium chloride) will be administered intramuscularly.

Locations

Country Name City State
Canada IWK Health Centre Halifax Nova Scotia

Sponsors (2)

Lead Sponsor Collaborator
Dalhousie University ImmunoVaccine Technologies, Inc. (IMV Inc.)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with adverse events as a measure of safety and reactogenicity of the intramuscular DPX-RSV(A) Up to 28 Days after first injection.
Secondary Number of participants with adverse events as a measure of safety of a second dose of the DPX-RSV(A) 180 days after vaccination.
Secondary The immunogenicity of the DPX-RSV(A) as measured by antibodies directed to the SHe antigen 28 days after one dose of vaccine and 28 days after a the second dose of a two-dose vaccine schedule as measured by antibodies directed to the SHe antigen.
Secondary Persistence of the humoral immune response to two doses of the RSV investigational vaccines, as measured by anti-SHe antibodies From Day 28 to Day 180 after second vaccination
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04528719 - A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive Phase 1
Terminated NCT02508194 - A Study to Evaluate the Efficacy of MEDI7510 in Older Adults Phase 2
Active, not recruiting NCT06060457 - A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age Phase 3
Terminated NCT01757496 - Cough Assist in Bronchiolitis N/A
Completed NCT00100373 - RSV Challenge in Healthy Adults N/A
Completed NCT03524118 - Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) Phase 1/Phase 2
Active, not recruiting NCT05572658 - Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
Recruiting NCT06067230 - A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults Phase 3
Completed NCT00246480 - RSV Disease in the Elderly
Active, not recruiting NCT06097299 - A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Phase 2
Completed NCT00889070 - Respiratory Events Among Premature Infants N/A
Unknown status NCT00613184 - Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses N/A
Completed NCT05559905 - Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) Phase 2
Active, not recruiting NCT05127434 - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age Phase 2/Phase 3
Terminated NCT04978337 - A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection Phase 2
Recruiting NCT06143046 - A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers Phase 2
Active, not recruiting NCT05397223 - A Study of Modified mRNA Vaccines in Healthy Adults Phase 1
Completed NCT01734668 - Sofia RSV FIA Field Study N/A
Completed NCT01562938 - MEDI-557 Adult Dosing Phase 1
Recruiting NCT06325657 - A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants Phase 3